Application of DNA Microarrays in Pharmacogenomics and Toxicogenomics

Many drugs or xenobiotics can induce specific or nonspecific cellular signal transduction events that activate various physiologic and pharmacologic responses including homeostasis, proliferation, differentiation, apoptosis, and necrosis. To minimize the insults caused by these xenobiotics, tissues and organs are equipped with protective mechanisms that either pump drugs out of the cells (e.g., the multidrug-resistant, mdr, family of proteins) or increase the level of detoxifying enzymes such as phase I and II drug-metabolizing enzymes (DMEs), after exposure to xenobiotics. This review discusses the molecular analysis of pharmaco- or toxicogenomic gene expression profiles following exposure to cancer chemotherapeutic and chemopreventive agents. We present the development of DNA microarray technology and its use in expression profiling of possible signal transduction events elicited by these compounds, and its potential future applications in drug discovery and development in the pharmaceutical industry.

[1]  Ronald W. Davis,et al.  Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray , 1995, Science.

[2]  David E. Misek,et al.  Gene-expression profiles predict survival of patients with lung adenocarcinoma , 2002, Nature Medicine.

[3]  Y. Kan,et al.  hMAF, a Small Human Transcription Factor That Heterodimerizes Specifically with Nrf1 and Nrf2* , 1997, The Journal of Biological Chemistry.

[4]  F. Collins,et al.  Mutational analysis using oligonucleotide microarrays , 1999, Journal of medical genetics.

[5]  R. Yu,et al.  Signal transduction events elicited by cancer prevention compounds. , 2001, Mutation research.

[6]  J. V. Moran,et al.  Initial sequencing and analysis of the human genome. , 2001, Nature.

[7]  R. Yu,et al.  Induction of xenobiotic enzymes by the map kinase pathway and the antioxidant or electrophile response element (ARE/EpRE),†,‡ , 2001, Drug metabolism reviews.

[8]  Y. ChanJ,et al.  酵母での遺伝的選択によるNF-E2関連転写因子、Nrf1のクローニング , 1993 .

[9]  Xi Zheng,et al.  Gene expression of TPA induced differentiation in HL-60 cells by DNA microarray analysis. , 2002, Nucleic acids research.

[10]  J. D. Engel,et al.  Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. , 1999, Genes & development.

[11]  S. P. Fodor,et al.  High density synthetic oligonucleotide arrays , 1999, Nature Genetics.

[12]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[13]  F. Wright,et al.  Assembly, annotation, and integration of UNIGENE clusters into the human genome draft. , 2001, Genome research.

[14]  M Roederer,et al.  Gene microarray identification of redox and mitochondrial elements that control resistance or sensitivity to apoptosis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Y. Kan,et al.  Isolation of cDNA encoding the human NF-E2 protein. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Jeffrey A. Johnson,et al.  Phosphatidylinositol 3-Kinase, Not Extracellular Signal-regulated Kinase, Regulates Activation of the Antioxidant-Responsive Element in IMR-32 Human Neuroblastoma Cells* , 2001, The Journal of Biological Chemistry.

[17]  Y. Kan,et al.  Cloning of Nrf1, an NF-E2-related transcription factor, by genetic selection in yeast. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[18]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[19]  A. Bird,et al.  Number of CpG islands and genes in human and mouse. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Downing,et al.  Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. , 2002, Cancer cell.

[21]  Meland,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[22]  Y. Mo,et al.  Activation of Mitogen-activated Protein Kinase Pathways Induces Antioxidant Response Element-mediated Gene Expression via a Nrf2-dependent Mechanism* , 2000, The Journal of Biological Chemistry.

[23]  Chun-Yuan Ting,et al.  26 S Proteasome-mediated Degradation of Topoisomerase II Cleavable Complexes* , 2001, The Journal of Biological Chemistry.

[24]  D. Mccormick.  Sequence the Human Genome , 1986, Bio/Technology.

[25]  A. Jaiswal,et al.  Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[26]  M. Bittner,et al.  Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. , 2000, Cancer research.

[27]  A. Kong,et al.  Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes. , 2002, Current drug metabolism.

[28]  J. Barrett,et al.  Application of complementary DNA microarray technology to carcinogen identification, toxicology, and drug safety evaluation. , 1999, Cancer research.

[29]  M. Grant,et al.  The toxicity of menadione and mitozantrone in human liver-derived Hep G2 hepatoma cells. , 1989, Biochemical pharmacology.

[30]  H. Huang,et al.  Regulation of the antioxidant response element by protein kinase C-mediated phosphorylation of NF-E2-related factor 2. , 2000, Proceedings of the National Academy of Sciences of the United States of America.